Genotypic Technology partners with PMC for rapid COVID-19 tests
The companies also plan to co-develop novel proteins for differential diagnostics of various infectious diseases such as Dengue, Chikungunya, Zika, Ebola and others
Genotypic Technology announced its partnership with Premier Medical Corporation (PMC) US for distribution of rapid antigen and antibody kits. PMC is a manufacturer of rapid tests of various diseases such as Malaria, HIV, Hepatitis B and C, Dengue and Syphilis, and has ISO certified manufacturing facilities in Gujarat, India. Genotypic collaborated with PMC during the first wave of COVID-19 to develop COVID-19 diagnostic products that will help in screening SARS CoV-2 in less than 20 minutes.
Rapid antibody tests can be used in deciphering the immune response of a person, determining whether the person has antibodies for SARS CoV-2, typically after COVID-19 infection or vaccination. Rapid Antibody tests have also been used in surveillance of SARS-CoV-2 which have helped in identifying undetected chains of disease transmission.
“Rapid Antigen and Antibody kits are CE marked, ICMR approved, and Antigen tests have also been listed by WHO under the Emergency Use Listing (EUL) category). These diagnostic products have been benchmarked by Genotypic along with other governmental and reputed private labs for performance, and have shown higher specificity and sensitivity compared to other diagnostic products available in the market,” informed a company release
Commenting on the announcement, Dr Raja Mugasimangalam, Founder and CEO, Genotypic Technology said, “There is an urgent need to expand point-of-care testing to keep the spread minimal and decrease the waiting time for the results, thus enabling immediate isolation. Antigen cards are ideally suitable for securing educational institutions, workplaces and events. I strongly believe that the rapid test will open gates for the travel and tourism industry to come back to business after the second wave of COVID-19. We have been using the antigen and antibody tests to safeguard Genotypic, Dhitiomics and QTLomics workplaces. Genotypic has been working with several technology companies to provide SARS-CoV-2 sequencing solutions to more than 1400 Indian COVID testing Labs.”
Commenting on the announcement, Nilesh Mehta, CEO & President, Premier Medical Corporation, NJ, USA, added “PMC and Genotypic have collaborated to develop antigen and antibody kits for COVID-19 to cater to the community to accelerate testing as per the new guidelines. In addition to this, we also plan to co-develop novel proteins for differential diagnostics of various infectious diseases such as Dengue, Chikungunya, Zika, Ebola and others.”